A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients

Immune Thrombocytopenic Purpura Clinical Trial

Official title:

Treatment of thromBocytopenia With EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients With Immune ThrombocytoPenia- BRIDGING ITP Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01621204
• Other study ID #: M-EIBS-A-12
• Status: Completed
• Phase: Phase 3
• Start date: October 2012
• Est. completion date: August 2019

Study information

• Verified date: September 2020
• Source: McMaster University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a study to investigate if eltrombopag can be used instead of Intravenous Immune Globulin (IVIG) in patients with ITP, to adequately raise their platelet count when they undergo minor or major surgery. Eltrombopag is a daily, oral pill approved for treatment of ITP. IVIG is a blood product frequently used to treat ITP. Patients with ITP who need surgery have to get treatment to increase their platelet count. IVIG is commonly used for this purpose but eltrombopag may be more effective and convenient for patients.

Description:

Immune thrombocytopenia (ITP) is a heterogeneous autoimmune disease characterized by the presence of platelet autoantibodies, low platelet counts and an increased risk of bleeding. TPO receptor agonists which stimulate platelet production have been shown to be remarkably effective in ITP. Their use as a short-term means of elevating platelet counts in preparation for surgical procedures has not yet been adequately evaluated.

Many patients with moderate to severe ITP (platelet count less than 50 x 10exp9/L) have stable platelet counts and do not bleed; however, when surgeries or invasive procedures become necessary, additional treatment is often required to increase the platelet count to achieve adequate hemostasis. Although specific guidelines for surgical platelet count thresholds in ITP are lacking, platelet transfusion guidelines recommend a platelet count of 50 - 100 x10exp9/L for the vast majority of surgical procedure; 50x10exp9/L is a typical threshold for minor surgeries like tooth extractions and endoscopies; and 100x10exp9/L is used for major surgery like cardiac surgery or neurosurgery.

Commonly, intravenous immunoglobulin (IVIG) is used to rapidly increase platelet counts in ITP patients before an invasive procedure. IVIG is associated with a transient platelet count response in approximately 80% of patients, which occurs within 2 - 4 days. In most patients, platelet counts remain elevated for approximately 4 weeks, allowing enough time to complete the procedure and for adequate post-operative hemostasis. However, IVIG is a resource-intensive and expensive blood product associated with frequent side effects.

Eltrombopag is a small molecule, non-peptide thrombopoietin (TPO) receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. TPO receptor agonists are an effective new class of medications that are non-immunogenic agonists of the TPO receptor (c-Mpl) and work by increasing platelet production in ITP patients. In randomized controlled trials, eltrombopag maintenance therapy has been shown to raise the platelet count in 60 - 80% of ITP patients and platelet counts generally remain elevated as long as the drug is continued. Time to response is 1 - 2 weeks with minimal need for dose titration. Side effects of eltrombopag observed in clinical studies included elevation of liver enzymes (approximately 10% of patients). The risk of thrombosis and bone marrow reticulin formation remain uncertain.

The investigators propose a randomized controlled trial (RCT) involving 74 patients (across approximately 8 centers) in Canada. This study will evaluate the efficacy and safety of eltrombopag bridging therapy compared with IVIG bridging therapy in adult patients with ITP who require surgery. This study will also evaluate bleeding, adverse events and patient-reported treatment satisfaction using the Treatment Satisfaction Questionnaire for Medication (TSQM). Patients will be stratified according to centre and surgery type (major vs. minor).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 74
• Est. completion date: August 2019
• Est. primary completion date: June 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Primary or secondary ITP;

• Platelet count below surgical platelet count threshold (50 x10^9/L for minor surgery; 100 x 10^9/L for major surgery);

• 18 years of age or older;

• On stable doses of concomitant ITP medications (i.e the dose administered has not changed) or no ITP medication for at least 2 weeks;

• At least 3-weeks lead time available between randomization and scheduled surgery;

• IVIG and Eltrombopag are acceptable ITP treatment options for this patient;

• Able to provide informed consent.

Exclusion Criteria:

• Pregnancy or breastfeeding;

• Treatment with IVIG within the last 2 weeks;

• Treatment with a thrombopoietin receptor agonist (eltrombopag or romiplostim) within the last 4 weeks;

• AST, ALT above 2X upper limit of normal;

• Bilirubin above 1.5X upper limit of normal in the absence of clinically benign liver disorder (eg. Gilberts syndrome);

• Deep vein thrombosis, myocardial infarction, thrombotic stroke or arterial thrombosis in the last 12 months;

• History of bone marrow reticulin or fibrosis;

• Known liver cirrhosis;

• Active malignancy (defined as requiring treatment or palliation within the last 6 months);

• Any additional laboratory test result, health related illness or other diagnosis which, in the opinion of the treating physician, may put the subject's health or safety at risk.

Related Conditions & MeSH terms

• Immune Thrombocytopenic Purpura
• Purpura
• Purpura, Thrombocytopenic
• Purpura, Thrombocytopenic, Idiopathic
• Thrombocytopenia

Intervention

Drug:
• Eltrombopag
Participants are started on 50mg daily oral pill (or 25mg daily for patients of East Asian descent) 21 days before surgery. Dose may be adjusted based on subsequent platelet counts (minimum 25mg; maximum 75mg).
• IVIG infusion
IVIG infusion (1-2 g/kg) given 7 (+/-2) days prior to surgery; with an additional infusion allowed within one week of achievement of surgical hemostasis, if needed

Locations

Country	Name	City	State
Canada	University of Alberta Hospital	Edmonton	Alberta
Canada	Hamilton Health Sciences	Hamilton	Ontario
Canada	London Health Sciences Center	London	Ontario
Canada	Hopital Maisonneuve-Rosemont	Montreal	Quebec
Canada	Jewish General Hospital	Montreal	Quebec
Canada	Ottawa Hospital	Ottawa	Ontario
Canada	St.Micheal's Hospital	Toronto	Ontario
Canada	Sunnybrook Hospital	Toronto	Ontario
Canada	Vancouver General Hospital	Vancouver	British Columbia
Netherlands	The Haga Hospital	The Hague

Sponsors (4)

Lead Sponsor	Collaborator
McMaster University	GlaxoSmithKline, Hamilton Health Sciences Corporation, Novartis

Countries where clinical trial is conducted

Canada,  Netherlands, 

References & Publications (1)

Arnold DM, Heddle NM, Cook RJ, Hsia C, Blostein M, Jamula E, Sholzberg M, Lin Y, Kassis J, Larratt L, Tinmouth A, Amini S, Schipperus M, Lim W, Vishnu P, Warner M, Carruthers J, Li N, Lane S, Kelton JG. Perioperative oral eltrombopag versus intravenous im — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Achievement of a platelet count level that is above the platelet count threshold for surgery preoperatively and that is maintained above the threshold during the post-hemostasis period without the use of rescue treatment	Threshold is a platelet count of 50 x 10^9/L for minor surgery and 100 x 10^9/L for major surgery.	For a the period of time from the final pre-operative visit until 7 days after surgical hemostasis is achieved
Secondary	Time to treatment failure	Time to the occurrence of a platelet count level below the designated threshold, or the administration of rescue treatment	During the period from the final pre-operative visit until 7 days after surgical hemostasis is achieved
Secondary	Surgical delays or cancellations	Proportion of patients with surgical delays or cancellations	Measured at time of planned surgery
Secondary	Bleeding	Graded as per the ITP bleeding score	During treatment and follow up (on average, 8 weeks from starting treatment)
Secondary	Thrombocytosis	Platelet count >400 x 10^9/L	During treatment and follow up (on average, 8 weeks from starting treatment)
Secondary	Blood product transfusions	Proportion of patients requiring platelet, red blood cells and plasma transfusions	During treatment and follow up (on average, 8 weeks from starting treatment)
Secondary	Rescue treatment	New ITP treatment (typically platelet transfusions, high dose IVIG or high dose corticosteroids) or an increased dose of existing ITP treatment administered to increase platelet counts above threshold	During the period from the final pre-operative visit until 7 days after surgical hemostasis is achieved
Secondary	Platelet count change over time	Trend of all platelet count measurements in the trial	During treatment and follow up (on average, 8 weeks from starting treatment)
Secondary	Patient satisfaction with treatment	Assessed using the Treatment Satisfaction Questionnaire for Medications Score vII (which incorporates effectiveness, convenience, side effects, and overall satisfaction)	Immediately before surgery (final pre-op visit) and 7 days (+/- 2 days) after surgical hemostasis is achieved
Secondary	Hospitalizations	Unanticipated admissions to hospital or prolongation of hospitalization	During treatment and follow up (on average, 8 weeks from starting treatment)
Secondary	Thrombosis	Symptomatic thrombotic events confirmed with diagnostic imaging	During treatment and follow up (on average, 8 weeks from starting treatment)
Secondary	Adverse Events	Defined using the Common Terminology Criteria for Adverse Events v3.0	During treatment and follow up (on average, 8 weeks from starting treatment)